innoscripta SE (ETR:1INN)

Germany flag Germany · Delayed Price · Currency is EUR
68.60
-0.60 (-0.87%)
At close: May 12, 2026
Market Cap686.00M
Revenue (ttm)103.41M +59.8%
Net Income42.61M +69.8%
EPS4.26 +69.8%
Shares Out10.00M
PE Ratio16.10
Forward PE11.96
Dividend4.00 (5.83%)
Ex-Dividend DateApr 22, 2026
Volume4,502
Average Volume6,957
Open68.70
Previous Close69.20
Day's Range68.10 - 71.50
52-Week Range61.10 - 137.00
Betan/a
RSI47.85
Earnings DateMay 15, 2026

About innoscripta SE

innoscripta SE provides software-as-a-service for managing research and development (R&D) tax incentives and project management consulting in Germany and France. It offers solutions for research and development documentation, such as human resources, task management, organization, project management, and time tracking. It serves the additive manufacturing/3D printing; aerospace engineering; automotive; biotechnology; business consulting and technical services; chemical; construction; electrical engineering; energy; environmental technology and ... [Read more]

Sector Technology
Founded 2012
Employees 322
Stock Exchange Deutsche Börse Xetra
Ticker Symbol 1INN
Full Company Profile

Financial Performance

In 2025, innoscripta SE's revenue was 103.41 million, an increase of 59.82% compared to the previous year's 64.71 million. Earnings were 42.61 million, an increase of 69.82%.

Financial Statements

News

innoscripta SE Earnings Call Transcript: Q4 2025

Revenue and EBIT surged nearly 60% year-over-year, driven by enterprise client wins and product innovation. Management expects continued high growth and margins, supported by regulatory tailwinds and international expansion, with a focus on shareholder returns.

3 months ago - Transcripts

innoscripta SE Earnings Call Transcript: Q2 2025

Half-year revenue surged 90% year-over-year to EUR 44.1 million, with EBIT more than doubling and margins reaching 58%. Strong customer growth, low churn, and regulatory changes are expected to further boost revenue, while cash flow and profitability remain robust.

9 months ago - Transcripts